Pharma BD Deal Intelligence
Dimerix granted Everest Medicines an exclusive license to commercialize DMX-200, a small molecule CCR2 inhibitor, for all indications including focal segmental glomerulosclerosis (FSGS), across Greater China, South Korea and six Southeast Asian markets. Dimerix receives USD 10 million upfront within 45 business days of execution and is eligible for up to USD 30 million in development and regulatory milestones and up to USD 300 million in commercial milestones, plus tiered royalties of 10-15% on net sales. DMX-200 is in the pivotal Phase 3 ACTION3 study in FSGS, a rare and serious kidney disease.